All Wales Medicines Strategy Group (AWMSG) recommends Sativex for the treatment of MS spasticity

  • Following a health technology appraisal, Sativex has been recommended for the treatment of MS spasticity by the All Wales Medicines Strategy Group (AWMSG)1

"Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®) is recommended as an option for use within NHS Wales as treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy."1

The AWMSG ( work in an advisory capacity to ensure equity of access to the most clinically appropriate and cost-effective medicines for the people of Wales. They bring together clinical experts, pharmacists, health economists, industry representatives and patient advocates to form a consensus on the use of medicines within primary and secondary care.